The $102 million charge for acquired in-process research and development (IPR&D) indicates significant recent investment in external innovation through new partnerships. This spending on new research creates potential needs for clinical trial support, R&D data management platforms, and financial systems to track milestone payments.
Filing excerpt
Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results... for the first quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $102 million on a pre-tax basis.
What this signalsFilings often name leadership changes, deals and spending plans.
sec-8kmaterialContractGet every 8-K signal for Regeneron and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”
The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/775a4d43-1f5c-439e-8575-b6e45e9b9dd4 returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.
{
"signal_id": "775a4d43-1f5c-439e-8575-b6e45e9b9dd4",
"signal_type": "sec-8k",
"signal_subtype": "materialContract",
"detected_at": "2026-04-14T06:58:48.274+00:00",
"company": {
"name": "Regeneron",
"domain": "regeneron.com"
},
"data": {
"detail": "The $102 million charge for acquired in-process research and development (IPR&D) indicates significant recent investment in external innovation through new partnerships. This spending on new research creates potential needs for clinical trial support, R&D data management platforms, and financial systems to track milestone payments.",
"metrics": {
"timeframe": "current_quarter",
"dollar_context": "Acquired in-process research and development (IPR&D) charge related to collaboration and licensing agreements.",
"dollar_millions": 102
},
"summary": "Regeneron discloses $102M charge for R&D collaboration and licensing agreements in Q1 2026.",
"excerpts": "Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) currently expects that its financial results... for the first quarter 2026 will include an acquired in-process research and development (“IPR&D”) charge of approximately $102 million on a pre-tax basis.",
"relevance": 0.9,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/872589/000110465926040661/tm2611354d1_8k.htm",
"filing_date": "2026-04-08",
"filing_year": 2026,
"sales_relevance": "Vendor relationship signal",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/775a4d43-1f5c-439e-8575-b6e45e9b9dd4 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"regeneron.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.